Quantcast

Latest Isis Stories

2014-07-02 23:12:44

Pharmica Consulting, the industry leader in life science processes and technology, is pleased to announce that Rich Crook of Isis Pharmaceuticals will speak at Pharmica’s SharePoint Conference for the Life Sciences Industry on September 30th and October 1st in San Diego, CA. San Diego, CA (PRWEB) July 02, 2014 As part of its continued service to the industry, Pharmica will host its 11th SharePoint conference in San Diego, CA on September 30 and October 1, 2014. The two-day conference...

2014-07-02 08:26:15

CARLSBAD, Calif., July 2, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million payment from GlaxoSmithKline (GSK) related to the advancement of its program to develop antisense drugs to treat hepatitis B virus (HBV). http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO "Our collaboration with GSK has been very productive resulting in three novel antisense drugs in our pipeline. We look forward to continuing to advance...

2014-06-24 08:29:49

CARLSBAD, Calif., June 24, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTR(Rx) in patients with familial amyloid polyneuropathy (FAP). http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO ISIS-TTR(Rx) is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and...

2014-06-17 08:28:25

CARLSBAD, Calif., June 17, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today it has earned a $10 million milestone payment from Biogen Idec associated with the validation of an undisclosed target to treat a neurological disorder. This is the first milestone payment under Isis' and Biogen Idec's 2013 strategic collaboration to advance the treatment of neurological disorders. This collaboration combines Biogen Idec's expertise in neurology with Isis'...

2014-06-16 08:27:42

Up to 2.25 percentage point reduction in HbA1c achieved after only 13 weeks of dosing CARLSBAD, Calif., June 16, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the final results from its Phase 2 study of ISIS-GCGR(Rx) in patients with type 2 diabetes uncontrolled on stable metformin therapy. In this study, patients in the per protocol population (PP) treated with ISIS-GCGR(Rx) in addition to metformin achieved absolute mean reduction in hemoglobin...

2014-06-12 08:28:34

CARLSBAD, Calif., June 12, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 2014 Wells Fargo Healthcare Conference at 1:10 p.m. ET and participate in the Gene Manipulation Panel at 2:20 p.m. ET on Tuesday, June 17, 2014 in Boston, MA. http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO A live webcast of the presentations will be available on the "Investors...

2014-06-11 08:28:25

Event and webcast scheduled on Monday, June 16 at 6:30 a.m. Pacific Time CARLSBAD, Calif., June 11, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will host an investor event and a live webcast on Monday, June 16, 2014 at 6:30 a.m. Pacific Time to discuss the ISIS-GCGR(Rx) Phase 2 data presented at the American Diabetes Association's 74(th) Scientific Sessions in San Francisco, CA. http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO...

2014-06-10 08:29:31

Successful collaboration with AstraZeneca includes two novel cancer drugs in clinical development CARLSBAD, Calif., June 10, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that AstraZeneca has initiated a Phase 1 clinical study of ISIS-AR(Rx) in patients with cancer. Isis earned a $15 million milestone payment associated with the clinical advancement of ISIS-AR(Rx). ISIS-AR(Rx) is an antisense drug designed to treat patients with prostate cancer by...

2014-06-09 08:28:10

Isis Earns $14 Million Milestone Payment from Biogen Idec CARLSBAD, Calif., June 9, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated a Phase 1 study for ISIS-DMPK(Rx). Isis earned a $14 million milestone payment from Biogen Idec associated with this achievement. ISIS-DMPK(Rx) is designed to reduce the production of toxic dystrophia myotonica-protein kinase (DMPK) RNA in cells, including muscle cells, for the treatment of...

2014-06-05 12:36:04

LONDON, June 5, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Mobile Wallet Technologies: Global Marketshttp://www.reportbuyer.com/telecoms/country_overviews_telecommunications/mobile_wallet_technologies_global_markets.html INTRODUCTIONTECHNOLOGIES AND APPLICATIONThis study provides thorough analysis of the market for mobile wallet technology. The market is segmented on the basis of technologies: mobile commerce--mobile payment solutions (taxi, hotel,...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.